Bioorthogonal PEGylation Prolongs the Elimination Half-Life of N-TIMP2 While Retaining MMP Inhibition

Keyphrases

• Elimination Half-life 100%
• N-terminal Domain 100%
• Matrix Metalloproteinase Inhibitors 100%
• Bioorthogonal 100%
• TIMP-2 100%
• PEGylation 100%
• MMP14 35%
• PEGylated 21%
• Matrix Metalloproteinases 14%
• Tissue Inhibitor of metalloproteinase-1 (TIMP-1) 14%
• Noncanonical Amino Acids 14%
• Mono-PEGylation 14%
• PEGylated Proteins 14%
• Biological Processes 7%
• Inhibitory Activity 7%
• Modified Proteins 7%
• Fold Increase 7%
• Active Sites 7%
• Conjugation 7%
• Biological Activity 7%
• Pharmacokinetic Profile 7%
• Circulation Half-life 7%
• Proteolysis 7%
• Potential Therapeutics 7%
• Natural Inhibitors 7%
• Lysine 7%
• Cysteine Residues 7%
• Extracellular Matrix Protein 1 (ECM1) 7%
• Binding Interface 7%
• Zn2+ 7%
• Cancer Development 7%
• Lysine Residue 7%
• Propargyl 7%
• Inhibition Studies 7%
• Azides 7%
• Serum Stability 7%
• In Vivo Pharmacokinetics 7%
• Life-limiting 7%
• Click Chemistry Reaction 7%
• Site-specific PEGylation 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Elimination 100%
• Matrix Metalloproteinase 100%
• PEGylation 100%
• Matrix Metalloproteinase 14 83%
• Amino Acid 33%
• Lysine 33%
• Pharmacokinetics 33%
• Tissue Inhibitor of Metalloproteinase 33%
• Mouse 16%
• Disease 16%
• Polyethylene Glycol 16%
• Malignant Neoplasm 16%
• Biological Activity 16%
• Cysteine 16%
• Azide 16%
• Zinc Ion 16%

Immunology and Microbiology

• Amino Terminal Sequence 100%
• PEGylation 100%
• Elimination Half-Life 100%
• Pharmacokinetics 18%
• Mouse 9%
• Extracellular Matrix 9%
• Protein Degradation 9%
• Biological Activity 9%
• Biological Phenomena and Functions Concerning the Entire Organism 9%
• Click Chemistry 9%